Fact-checked by Grok 2 weeks ago

Ge Li

Ge Li (Chinese: 李革; born January 1967) is a Chinese-American , entrepreneur, and philanthropist best known as the founder, chairman, and CEO of , a global leader in contract research, development, and manufacturing services for the pharmaceutical and industries. Born in China, Li earned a bachelor's degree in chemistry from in 1989 and a Ph.D. in from in 1994. After serving as a founding at Pharmacopeia Inc. from 1993 to 2000, he established WuXi PharmaTech (later rebranded as ) in in 2000, pioneering an integrated, open-access R&D platform that has revolutionized outsourced and development. Under his leadership, the company grew rapidly, listing on the in 2007 (before delisting in 2015) and achieving dual listings on the and stock exchanges in 2018; by 2024, employed over 38,000 people worldwide and reported annual revenues exceeding $5.5 billion. Li, a U.S. citizen with permanent residency in , has been recognized for his contributions to the biopharma sector, including the of the CRDMO (contract , , and ) model that supports innovators in advancing medicines from discovery to commercialization. Through the Ge Li & Ning Zhao Family Foundation, he has made substantial philanthropic commitments to and , including a $21.5 million gift to Columbia University's Department of Chemistry in 2020 to advance and teaching, a $20 million donation to in 2021 for initiatives, and a $10 million contribution to Dana-Farber Cancer Institute in 2024 to establish the Ning Zhao and Ge Li Family Initiative in Nursing.

Early life and education

Early life

Ge Li was born in January 1967 in China. He attended the Affiliated High School of Peking University, where he completed his secondary education in the 1980s. Following his high school graduation, he entered Peking University for higher education.

Higher education

Ge Li earned a bachelor's degree in chemistry from Peking University in Beijing in 1989. He then pursued advanced studies in the United States, completing a Ph.D. in at in 1994. Li's doctoral research centered on techniques, with a particular emphasis on creating synthetic receptors for peptides that could enable sequence-selective binding, laying groundwork for applications in pharmaceutical . A key contribution from this period was his involvement in developing peptidosteroidal receptors targeted at peptides, employing combinatorial library methods to achieve selective interactions, as co-authored in a 1994 Journal of the paper under the supervision of W. Clark Still. This training under Still, a leader in computational and molecular design, honed Li's skills in innovative synthesis strategies essential for advancing therapeutic compound development.

Professional career

Early professional experience

Ge Li joined Pharmacopeia, Inc. as a founding in 1993 in , earning his Ph.D. in from in 1994, where he applied his expertise to early-stage in a burgeoning biotech environment. At the company, which specialized in innovative platforms for pharmaceutical research, Li immersed himself in the competitive U.S. biotech landscape, gaining hands-on experience in scaling technologies from academic concepts to commercial applications. Li's primary contributions at Pharmacopeia centered on advancing and methodologies, notably through work on the ECLiPS (Encoded Combinatorial Libraries on a ) technology. This platform facilitated the efficient encoding and synthesis of vast libraries of small-molecule compounds, enabling to identify potential candidates more rapidly than traditional methods. His efforts supported key partnerships, including a 1994 collaboration with to develop compounds for cancer and treatments, demonstrating the practical impact of these innovations on pharmaceutical pipelines. In 1999, while still at Pharmacopeia, Li traveled to China with senior colleague John J. Baldwin to assess opportunities for outsourcing combinatorial chemistry services, including meetings with potential partners such as the Jiangsu Taihushui Group. This exposure to 's emerging scientific infrastructure and talent pool, contrasted with the high costs and regulatory hurdles of U.S.-based operations, profoundly influenced Li's perspective on global R&D dynamics. His time at Pharmacopeia thus equipped him with critical insights into biotech entrepreneurship, emphasizing the value of integrated, technology-driven approaches to .

Founding and development of WuXi AppTec

In 2000, Ge Li co-founded WuXi AppTec in Shanghai, China, alongside his wife Ning Zhao, establishing it as a contract research organization (CRO) with an initial laboratory spanning 7,000 square feet. The company was launched to provide open-access research and development (R&D) services to global biopharmaceutical clients, drawing on Li's prior experience as a founding scientist at Pharmacopeia, where he helped develop a blueprint for integrated outsourcing platforms. From the outset, WuXi AppTec targeted international pharmaceutical firms by offering cost-effective chemistry services, securing early clients like Merck & Co. in 2002. The early years presented significant challenges in , including the need to construct specialized infrastructure and attract qualified talent in a nascent biotech sector. addressed these by securing initial investments from local entities, such as the Jiangsu Taihushui Group, and obtaining loans from state banks to build facilities, including a $7.2 million site in Jinshan by 2003. For talent acquisition, the company hired rapidly from China's expanding pool of graduates—reaching 300,000 annually by the early —employing 48 staff, including 27 PhDs, in its first year and investing in English training and advanced lab systems to meet global standards. These efforts enabled the firm to grow to 252 employees by 2003 while fostering trust with overseas partners through transparent online monitoring tools. Key milestones marked WuXi AppTec's evolution from a chemistry-focused to a full , development, and (CRDMO) model during the . The company launched synthetic chemistry services in 2001, followed by process development in 2003 and R&D-scale in 2004, allowing it to offer end-to-end support for and production. Further expansions included bioanalytical services in 2005 and / capabilities in 2007, alongside new campuses to scale operations. A pivotal 2008 acquisition of U.S.-based AppTec Laboratories for $163 million integrated biologics expertise and established a footprint, solidifying the CRDMO platform.

Leadership roles and achievements

Ge Li has served as Chairman and of since founding the company in 2000, guiding its transformation into a global leader in pharmaceutical , , and services. Under his stewardship, the executive structure evolved in recent years to include Co-CEOs Minzhang Chen and Steve Yang, enhancing operational depth while Li maintains overall strategic direction as Chairman and CEO. This has driven key milestones, including the company's initial public offering on the in 2007, its delisting in 2015 to prioritize Asian markets, listings on the in May 2018 and the in December 2018, and the opening of a process and facility in in 2016 to bolster U.S. operations. Li pioneered the development of integrated, open-access R&D platforms at , enabling seamless collaboration across , preclinical testing, and for biotech and pharmaceutical clients worldwide. These innovations have positioned as a comprehensive contract research, development, and organization (CRDMO), supporting accelerated timelines and contributing to recent financial successes, such as a 18.6% year-over-year increase to RMB 32.86 billion for continuing operations in the first nine months of 2025. Li's achievements have earned him significant recognition in the industry. In 2021, ranked him fourth among the best CEOs in for his visionary leadership in biopharma services. As of November 2025, estimates his net worth at $7.2 billion, primarily derived from his approximately 9% stake in held through entities G&C VI Limited and G&C V Limited, as reported in the company's semi-annual filings.

Philanthropy

Educational donations

In 2018, Ge Li and his wife, Ning Zhao, donated 100 million RMB (approximately $15 million USD at the time) to , their alma mater, to establish the Li Ge-Zhao Ning Education Fund. This fund supports the recognition of outstanding students through awards and aids the university's broader educational initiatives, particularly in fostering talent in science and research fields. The donation reflects their commitment to repaying the institution that shaped their early academic foundations, with Li expressing gratitude toward his teachers and a deep affection for the university. In 2024-2025, Ge Li and the Ge Li & Ning Zhao Family Foundation each donated more than $1 million to , a preparatory school in , to support its educational programs. Building on their philanthropic efforts, Li and Zhao made a significant $21.5 million gift to University's Department of Chemistry in , where both earned their PhDs in . The contribution establishes two endowed professorships equipped with startup funds for new laboratories, one endowed fellowship for graduate students, and one endowed scholarship for undergraduates pursuing chemistry studies. These initiatives aim to enhance research capabilities and teaching excellence in chemical sciences, underscoring the couple's desire to give back to the programs that advanced their professional trajectories.

Health research contributions

Ge Li has made significant philanthropic contributions to health research, particularly in , through the Ge Li & Ning Zhao Family Foundation, which he co-founded with his late wife in 2020. In 2021, the foundation donated $20 million to (MSK) to establish the Ning Zhao & Ge Li Family Initiative for Research and New Therapies, aimed at advancing understanding of biology and developing innovative treatments. This initiative supports multidisciplinary research efforts, including early detection, precision medicine, and therapeutic development, leveraging MSK's expertise in translational . These donations align with WuXi AppTec's expertise as a global provider of integrated biopharma research, development, and services, enabling more efficient processes. Following the death of Ning Zhao in May 2023 after a 20-year battle with cancer, Ge Li expanded the foundation's health to further support advancements. In June 2024, the foundation gave $10 million to Dana-Farber Cancer Institute, the largest single gift for its nursing program, creating the Ning Zhao & Ge Li Family Initiative in Nursing to enhance education, , and patient care integration with research. Building on this momentum, in 2025, the foundation endowed the Ning Zhao Chair of Nursing at within , honoring Zhao's legacy and bolstering and training in cancer care. These efforts reflect a commitment to bridging research and practical healthcare delivery, particularly in areas like where accessibility to advanced therapies remains a global challenge.

Controversies and political involvement

Ties to Chinese government

Ge Li has maintained long-term involvement with the (CCP) through his leadership at , where he has actively promoted Party activities and membership among employees since the company's early years. By , over 1,000 of the company's approximately 7,000 employees were CCP members, with Li emphasizing their role as the "technical backbone" of the . Li has personally attended and supported CCP events within , commending the work of Party branches and urging members to demonstrate their affiliation visibly. In a statement, he remarked, “Party members ‘Show your affiliation’ + Party branches ‘display your badges’ = the image of the ,” highlighting his encouragement for active participation in company governance and operations. This involvement aligns with broader CCP strategies to embed Party structures in private enterprises, fostering alignment with national priorities in the biopharma sector. WuXi AppTec has engaged in collaborations with Chinese state-backed research institutions and military entities, as documented in 2024 reports. The company was selected by the Ministry of Science and Technology to operate the State Key Laboratory of Drug Lead Compound Research, receiving support from both economic development programs and the (). Its employees co-invented treatments for with PLA scientists from the PLA between 2018 and 2023, resulting in at least 10 patents filed in the U.S., , and China. Additionally, has sponsored events praising CCP policies and received investments from PLA-linked funds, such as the Aviation Industry Corporation of China Fund. These partnerships extend to joint research with the PLA Academy of Military Medical Sciences, including lectures and awards for PLA researchers. The growth of in the 2000s was supported by Chinese government policies aimed at bolstering the sector. Founded in 2000, the company benefited from local government incentives in , including tax breaks and preferential land use rights, which facilitated its rapid expansion. By 2007, these supports enabled its listing on the , amid national initiatives to promote innovation in pharmaceuticals and contract research services. Such policies reflected broader efforts under the 10th and 11th Five-Year Plans to integrate private firms into state-driven development in high-tech industries.

US-China relations and BIOSECURE Act

Ge Li and have faced heightened scrutiny amid escalating U.S.- geopolitical tensions, particularly concerning risks in the sector. The BIOSECURE Act, initially introduced in the in January 2024, aimed to restrict federal funding and collaborations with certain Chinese companies deemed "biotechnology companies of concern." Early versions of the bill explicitly named due to alleged ties to the Chinese government that could threaten U.S. security. If enacted in that form, the legislation would have prohibited U.S. pharmaceutical and firms from engaging in contracts with for services such as and manufacturing, potentially disrupting the company's extensive U.S. operations, including its facility focused on process R&D and GMP manufacturing. reported a 17% revenue decline in its Advanced Therapies unit through the third quarter of 2024, attributing part of the impact to early effects of the bill's passage in the and ongoing Senate deliberations. However, as of November 2025, the bill has been revised in a version known as "BIOSECURE 2.0," passed by the on November 3, 2025, as an amendment to the (NDAA). This updated version does not explicitly name or ; instead, it relies on the Department of Defense's Section 1260H list of Chinese military companies, which does not include them. The and versions are undergoing , with final enactment expected before the end of 2025, though the revisions have reduced the direct threat to WuXi. In line with this, reported strong financial performance in 2025, with total revenue from continuing operations up 22.5% year-over-year to RMB 32.45 billion in the first nine months, and U.S. revenues increasing 31.9% to approximately $3.1 billion, indicating recovery from earlier concerns. In response to these allegations, Ge Li, as chairman and CEO of , co-signed an on February 3, 2024, alongside other company executives, asserting that the firm has operated for over 20 years without posing a risk to any country and emphasizing its adherence to and standards. The letter directly addressed claims of and ties, denying any involvement in such activities and highlighting WuXi's contributions to global biopharma . Reports from think tanks have amplified these concerns, with the Jamestown Foundation's February 2024 analysis, "Red Genes: Assessing AppTec's Ties to the Party-Army-State," detailing potential vulnerabilities in U.S. biopharma s stemming from 's alleged connections to the and , urging greater caution in partnerships. A related May 2024 report by security analyst James C. Mulvenon further examined Group's and links, reinforcing risks to U.S. through integrated dependencies. Ge Li has consistently responded to these developments by reiterating WuXi AppTec's commitment to compliance with global regulations and ethical standards, stating in a March 2024 Hong Kong stock exchange filing that the company poses no security threat to the U.S. or any other nation. He has emphasized the firm's independent operations and focus on serving international clients while navigating these tensions.

Personal life

Family

Ge Li married Ning Zhao in the 1990s during their time as doctoral students in at , where Li earned his PhD in 1994 and Zhao in 1995. Zhao held a in chemistry from . The couple co-founded in in 2000, with Zhao serving as executive director of the board and corporate senior vice president until her death on May 16, 2023, at age 56, following a 20-year battle with cancer. The couple's decision to return to and establish reflected a shared commitment, as Zhao left her role at Bristol-Myers Squibb to join Li in building the venture. They had children, including a son, Michael Li, evidenced by the creation of a children's irrevocable in 2006 for which Zhao served as , though specifics about their family life remain private and there are no public records of the children's involvement in business or . The Ge Li & Ning Zhao Family Foundation, established by the couple, underscores their emphasis on family-oriented giving in and .

Citizenship and residences

Ge Li holds citizenship, acquired through his advanced education at and subsequent professional career in the American pharmaceutical sector. He also possesses a permit for the , enabling long-term residency despite China's non-recognition of dual nationality. Li's primary residence is in , , aligning with the headquarters of and his central role in the company's operations. His business commitments sustain a notable presence in the United States, where WuXi maintains key facilities, including expanded sites in for testing and operations in among other locations. In his lifestyle, Li engages actively in global scientific discourse, participating in panel discussions at international conferences such as the Future Forum's Workshop on Future Medicine in 2017, where he discussed advancements in treatments for diseases. He further supports international initiatives through oversight of the Ge Li & Ning Zhao Family Foundation, a U.S.-based entity that funds cross-border efforts in scientific research and education. Post-2023, Li divested from certain U.S. properties, including the sale of a 9,499-square-foot waterfront mansion in , in May 2025 for $12.15 million—a property he had acquired in 2021 for approximately $9.13 million—while retaining his base in amid ongoing global .

References

  1. [1]
    Bloomberg Billionaires Index - Li Ge
    Li was born in January 1967. He graduated from Peking University with a bachelor's degree in chemistry in July 1989. Li obtained a Ph.D. degree in organic ...
  2. [2]
    Our Leadership - WuXi AppTec
    Ge Li, Ph.D. Chairman and CEO. Scientist and entrepreneur leading WuXi AppTec since its founding in 2000. Dr. Li pioneered an integrated, open-access R&D ...Missing: biography - | Show results with:biography -
  3. [3]
    Columbia Chemistry Receives $21.5 Million Gift from Dr. Ge Li and ...
    Jul 28, 2020 · Columbia University announced a $21.5 million gift from Dr. Ge Li '94GSAS and Dr. Ning Zhao '95GSAS to advance research and teaching in chemistry.
  4. [4]
    Memorial Sloan Kettering Announces New Initiative to Focus on ...
    May 13, 2021 · MSK today announced a $20 million gift from the Ge Li & Ning Zhao Family Foundation to support lung cancer research and the development of ...
  5. [5]
    Dana-Farber Cancer Institute receives $10 million gift from the Ge Li ...
    Jun 7, 2024 · The Ge Li & Ning Zhao Family Foundation has made an extraordinary gift of $10 million to Dana-Farber Cancer Institute, the largest single gift in support of ...
  6. [6]
    Ge Li - Grizzly Bulls Billionaire Index
    In 1989, he graduated with a B.A. from Peking University. Li pursued his Ph. D. in organic chemistry at Columbia University.
  7. [7]
    Columbia Chemistry Receives $21.5 Million Gift from Alumni Dr. Ge ...
    Jul 30, 2020 · In 2000, Dr. Li founded WuXi AppTec, a worldwide provider of research, development and manufacturing services for pharmaceutical and biotech ...Missing: biography early
  8. [8]
    Peptidosteroidal Receptors for Opioid Peptides. Sequence-Selective ...
    Peptidosteroidal Receptors for Opioid Peptides. Sequence-Selective Binding ... Click to copy article linkArticle link copied! Rustum Boyce · Ge Li · H ...
  9. [9]
    US5804563A - Synthetic receptors, libraries and uses thereof ...
    Chemical & Material Sciences Organic Chemistry ... Ge Li; Current Assignee. The listed assignees may ... Application filed by Columbia University in the City of New ...
  10. [10]
    [PDF] W. Clark Still – from flash chromatography to computational chemistry
    Sep 7, 2023 · Ge Li (Borned in 1967). 1989 B.Sc. Peking University. 1994 Ph.D. Columbia University, Advised by Clark W. Still. 1993-2000 Pharmacopeia Inc ...
  11. [11]
    The Scripps Research Institute Announces New Board Members ...
    Feb 27, 2017 · Prior to founding WuXi in 2000, Li was a founding scientist at Pharmacopeia Inc., a leading combinatorial chemistry platform company. Li has ...Missing: biography early
  12. [12]
  13. [13]
  14. [14]
    Our History - WuXi AppTec
    WuXi AppTec launched synthetic chemistry services in 2001, followed by process development services in 2003. In 2004, the company initiated manufacturing ...Missing: CRO | Show results with:CRO
  15. [15]
    Pharma Billionaire Zhao Ning Dies At 56 After Battling Cancer For ...
    May 17, 2023 · Zhao Ning, the billionaire cofounder of Shanghai- and Hong Kong-listed pharmaceutical research firm WuXi AppTec, has passed away at the age of 56 after ...Missing: co- | Show results with:co-
  16. [16]
    [PDF] A Chinese Pharmaceutical Startup Acquires an American Firm to ...
    This case study explores WX's history and acquisition of AppTec in 2008. It provides an analysis of WX's spectacular growth and success in China, the.
  17. [17]
    C&EN profiles WuXi AppTec, Chinese contract research giant
    If anybody knows what types of drug candidates or research methodologies are likely to be successful, it should be Ge Li ... in organic chemistry from Columbia ...
  18. [18]
  19. [19]
    WuXi AppTec Lists H Shares on the Hong Kong Stock Exchange
    Dec 12, 2018 · WuXi AppTec listed 116 million H-shares at HK$68 per share, raising HK$7,553 million. The funds will be used to enhance capabilities and ...
  20. [20]
    WuXi AppTec's STA Subsidiary Opens Operations in San Diego
    Aug 7, 2016 · SHANGHAI and San Diego, August 8, 2016 – WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving ...
  21. [21]
    WuXi AppTec Achieves Strong Double-Digit Growth in Revenue and ...
    Oct 26, 2025 · For the first three quarters of 2025, total revenue reached RMB32.86 billion, up 18.6% year-over-year. Revenue from Continuing Operations ...
  22. [22]
    Xiaomi's Lei Jun Tops 2021 Forbes China Best CEOs List
    Jul 15, 2021 · 1. Lei Jun, 51, Xiaomi · 2. Hu Yangzhong, 56, Hangzhou Hikvision · 3. Wang Chuanfu, 55, BYD · 4. Li Ge, 54, Wuxi AppTec · 5. Li Zhenguo, 53, LONGi ( ...
  23. [23]
    Li Ge - Forbes
    Li holds a Ph.D. in organic chemistry from Columbia University. His wife and Wuxi Apptec cofounder Zhao Ning passed away in 2023, at age 56, after battling ...
  24. [24]
    Alumni couple Li Ge and Zhao Ning donates 100 million RMB to ...
    Jun 15, 2018 · This time, Li and Zhao donated 100 million RMB to set up the Lige-Zhaoning Education Fund of Peking University as a reward for excellent ...
  25. [25]
    Peking U receives record donation of 1b yuan - Chinadaily.com.cn
    Mar 3, 2021 · He said the donation was a show of gratitude to the teachers and of love for his alma mater. Li has made 180 million yuan in donations to the ...Missing: Ge Columbia
  26. [26]
    Gift Advances Research & Teaching in Chemistry - Columbia Giving
    ... Dr. Ge Li '94GSAS and Dr. Ning Zhao '95GSAS. Li and Zhao both earned their doctorates in organic chemistry at Columbia.<|control11|><|separator|>
  27. [27]
    Memorial Sloan Kettering receives $20 million for lung cancer ...
    Memorial Sloan Kettering Cancer Center has announced a $20 million gift from the Shanghai-based Ge Li and Ning Zhao Family Foundation in support of lung cancer ...
  28. [28]
    Northwell celebrates newly endowed chairs and professors
    Nov 3, 2025 · Ning Zhao Chair of Nursing at Lenox Hill Hospital, endowed by the Ge Li and Ning Zhao Family Foundation. Dr. Browne has been a nurse for 38 ...Missing: contributions | Show results with:contributions
  29. [29]
    None
    ### Summary of WuXi AppTec and Ge Li’s Ties to Chinese Government
  30. [30]
    Red Genes: Assessing WuXi AppTec's Ties to the Party-Army-State ...
    Feb 9, 2024 · The company's claims are undermined by WuXi Apptec's network of relationships with the Chinese Communist Party (CCP), involvement in the ...
  31. [31]
    Staff at drugmaker under U.S. scrutiny worked with Chinese military ...
    Jun 6, 2024 · Employees of drugmaker WuXi AppTec, under U.S. scrutiny for its links to the Chinese military, co-invented altitude sickness treatments with ...
  32. [32]
    US Senate bill targeting China's BGI, WuXi AppTec moves forward
    Mar 6, 2024 · WuXi AppTec, which provides R&D and manufacturing services to the pharmaceutical and healthcare industry, allegedly has ties to the Chinese ...<|separator|>
  33. [33]
    WuXi AppTec plays defense against 'unfounded' allegations
    Feb 5, 2024 · ... Chinese Communist Party. “We strongly object to blanket allegations and preemptive actions against our company without due process,” the ...
  34. [34]
    San Diego, California, USA - STA Facility
    Discover WuXi STA's cutting-edge facility in San Diego, USA. Explore our world-class capabilities and expertise in pharmaceutical development.Missing: 2016 | Show results with:2016<|control11|><|separator|>
  35. [35]
    Biosecure Act's impact became clearer | C&EN Global Enterprise
    Dec 9, 2024 · WuXi blames the Biosecure Act for a 17% decline in WuXi Advanced Therapies' revenue through the third quarter of this year. Meanwhile, the bill ...
  36. [36]
    An Open Letter to our Customers from WuXi AppTec Leadership
    Feb 3, 2024 · We want to be clear and set the record straight: WuXi AppTec does not pose a national security risk to any country. While the U.S. government ...Missing: defending military ties
  37. [37]
    Is WuXi Apptec An Enemy Of The State - Outsourced Pharma
    Feb 20, 2024 · In an open letter, Ge Li, Ph.D ... Western-based Pharma assists the development of China's industry, the China Communist Party (CCP) by...
  38. [38]
    [PDF] The WuXi Group: The National Security Risks Associated with its ...
    The WuXi Group's founder, Li Ge, graduated from Peking University in 1989 and later received a PhD in organic chemistry from Columbia University in the United ...
  39. [39]
    Exclusive Interview: WuXi AppTec Responds To BIOSECURE Act
    May 13, 2024 · Ge Li, a Chinese American entrepreneur and founder of WuXi AppTec, that he was retiring from Pfizer, Li responded he had appreciated how ...
  40. [40]
    Chemical Science Gets $21.5M Boost | Columbia Magazine
    Li is the founder, chairman, and CEO of WuXi AppTec, a company that provides research, development, and manufacturing services to the pharmaceutical and ...Missing: biography early life
  41. [41]
    Zhao Ning - Forbes
    The couple's Ge Li & Ning Zhao Family Foundation supports education, scientific research, and healthcare innovations; it donated $20 million to the Memorial ...
  42. [42]
    Obituary – Mourning the Passing of Dr. Ning Zhao - WuXi Biologics
    May 17, 2023 · Dr. Zhao will be deeply missed. Her vision and spirit will live on through all of us, and guide the Company forward towards a future where “ ...Missing: AppTec | Show results with:AppTec
  43. [43]
    [PDF] A Chinese Pharmaceutical Startup Acquires an American Firm to ...
    Ge Li and John J. ... WX agreed to provide. Pharmacopeia's clients synthesis of combinatorial chemistry templates, compound libraries, and individual compounds.<|control11|><|separator|>
  44. [44]
    EX-99.(A)(1) - SEC.gov
    Oct 20, 2015 · Ge Li, chairman of the board of directors, chief executive officer ... Children's 2006 Irrevocable Trust, for which Ning Zhao is the ...
  45. [45]
    WuXi AppTec - 603259.SH - Board & Executives - Stock.us
    Ge Li (Li Ge), male, born in January 1967, doctor, American nationality, has obtained the permanent residence permit of the people's Republic of China.
  46. [46]
    WuXi AppTec Expands Site in the U.S. for Drug Development ...
    Apr 18, 2018 · In addition to the New Jersey site, WuXi also has U.S. facilities in Philadelphia (PA), St. Paul (MN), Atlanta (GA), San Diego (CA), Boston (MA) ...Missing: residences | Show results with:residences
  47. [47]
    【Workshop VII: Future Medicine】The Cure for Chronic Disease
    16:52 - 17:12 Keynote speech. Single Cell Genomics: When ... Ge LI, Founder, Chairman and CEO, WuXi AppTec, Member, Council of the Future Forum ...
  48. [48]
    Ge Li & Ning Zhao Family Foundation - Nonprofit Explorer - ProPublica
    Summary charts: organization finances over time · Revenue. $15.8M (2023) · Expenses. $12.6M (2023) · Total Assets. $283M (2023) · Total Liabilities. $0 (2023).
  49. [49]
    Pharma billionaire sells Fort Lauderdale mansion for $12 million
    May 2, 2025 · Billionaire Li Ge sold Fort Lauderdale mansion for $12.15 million. · Home features six bedrooms, pool, and dock on 13,000-square-foot site. · Ge ...Missing: residence | Show results with:residence
  50. [50]
    Resi Roundup: Billionaire Li Ge Sells Fort Lauderdale Mansion
    May 9, 2025 · Deals spanned Miami Beach to North Palm Beach, and ranged in price from $8.2 million to $12.3 million. Miami Beach. In Miami Beach, a ...
  51. [51]
    Biotech executive buys Fort Lauderdale mansion (Photos)
    Jul 15, 2021 · It was founded in 2000 by Zhao and her husband, Ge Li, the company's chairman and co-CEO. In 2020, Li and Zhao made a $21.5 million donation ...<|control11|><|separator|>